SeqOne a leader in AI-driven genomic analysis, has announced its acquisition of Congenica, a UK-based company specializing in clinical genomics. This strategic move creates the largest global 'software pure player' in the clinical genomics space, which will continue to have a presence in the UK at the Wellcome Sanger Institute. The acquisition merges SeqOne’s AI-powered platform for Next-Generation Sequencing (NGS) analysis with Congenica’s clinical decision support and interpretation services. The combined offering aims to tackle the 'interpretation bottleneck'—the challenge of analyzing vast amounts of genetic data—by transforming complex genomic data into rapid, actionable insights. This will accelerate diagnoses for rare diseases and enable more personalized cancer therapies.

The integrated company will serve over 160 customer laboratories in more than 30 countries and employ over 125 people. SeqOne plans to ensure continuity of service for Congenica customers, providing them with access to an expanded and integrated product portfolio. The acquisition follows a period of significant growth for SeqOne, which has recently doubled its revenue and expanded its international presence. The company also recently acquired Life & Soft and secured a €20 million funding round. The combined entity is expected to enable over 200,000 patient genomic analyses in 2025, a threefold increase from 2024. Leaders from both companies and Genomics England, a partner of Congenica, have expressed support for the combination, highlighting its potential to advance patient care through enhanced technology and expertise. The financial terms of the deal were not disclosed.